Mary Kerr (Nerre Therapeutics Ltd.)

Kerr, Mary (Nerre Therapeutics 201510– CEO before GSK + Advent Life Sciences)

	Organisation	Nerre Therapeutics Ltd.
	Former/major organisation	Kandy Therapeutics Ltd.
	Group	Bayer (Group)
	Product	NK receptor antagonist (neurokinin receptor antagonist)
	Product 2	drug development
	Source	Bayer AG. (8/11/20). "Press Release: Bayer to Acquire UK-based Biotech Kandy Therapeutics Ltd. [Not intended for U.S. and UK Media]". Berlin.

Record changed: 2023-09-25

Picture Swiss Biotech Association Swiss Biotech Days 2024 SBD24 Basel 650x200px

More documents for Mary Kerr

[1] Nerre Therapeutics Ltd.. (7/7/21). "Press Release: Nerre Therapeutics Raises £20 Million in a Series B2 Financing Round". Stevenage....
[2] Bayer AG. (8/11/20). "Press Release: Bayer to Acquire UK-based Biotech Kandy Therapeutics Ltd. [Not intended for U.S. and UK Media]". Berlin....
[3] Kandy Therapeutics Ltd.. (8/29/18). "Press Release: Kandy Therapeutics Successfully Raises £25 Million in a Series C Financing". Stevenage....
[4] Kandy Therapeutics Ltd.. (9/27/17). "Press Release: Kandy Therapeutics Launched to Advance a Breakthrough Treatment in Women's Health". Stevenage....
[5] Nerre Therapeutics Ltd.. (1/5/17). "Press Release: Nerre Therapeutics Raises £23 Million in Oversubscribed Series B Financing Round". Paris & Boston, MA....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]